In addition to antagonist treatment, a nanoplatform, siRNA-CaP-rHDL (ATF5 siRNA loaded by calcium phosphate into high-density lipoprotein apolipoprotein E3 nanoparticles), was built to deliver ATF5 siRNA safely and efficiently in glioblastoma cells, both in vitro and vivo, providing new insights into ATF5-targeted treatments [88]. Here, ATF5 is linked to glioblastoma.